Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481735 | 0.87 | AURKA (0.50) | SYKBTKAURKA | |
| SCHEMBL2479645 | 0.85 | SYK (0.48) | SYKAURKA | |
| SCHEMBL19973348 | 0.85 | SYK (0.48) | SYKAURKA | |
| SCHEMBL2480172 | 0.83 | SYK (0.48) | SYKBTKAURKA | |
| SCHEMBL2482190 | 0.82 | SYK (0.66) | SYKBTKAURKA | |
| SCHEMBL2524412 | 0.82 | SYK (0.71) | SYK | |
| SCHEMBL2481568 | 0.82 | SYK (0.50) | SYKBTKAURKA | |
| SCHEMBL2896223 | 0.80 | SYK (0.65) | SYKBTKAURKA | |
| SCHEMBL13337679 | 0.80 | SYK (0.59) | SYK | |
| SCHEMBL2480546 | 0.80 | SYK (0.50) | SYKBTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018195471-A1 | SYK INHIBITORS IN COMBINATION WITH HYPOMETHYLATING AGENTS | GILEAD SCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| WO-2018053189-A2 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20180071303-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3123864-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| US-8455493-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8450321-B2 | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor | GILEAD CONNECTICUT, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450321-B2 | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor | GILEAD CONNECTICUT, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885BTK 2/4885AURKA 794/4885 |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885BTK 2/4885AURKA 794/4885 |
| US-20180071303-A1 | SYK INHIBITORS | SYK, LCK, MERTK | SYK 1/4885BTK 6/4885AURKA 209/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885BTK 2/4885AURKA 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.